Oral ixazomib maintenance therapy in multiple myeloma.
Offidani M, Corvatta L, Gentili S, Maracci L, Leoni P.
Expert Rev Anticancer Ther · review; journal article · DOI 10.1586/14737140.2016.1123627 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för ixazomib. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
21 hitsKRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
Chattopadhyay N, Berger AJ, Koenig E, Bannerman B, Garnsey J, Bernard H, Hales P, Maldonado Lopez A, Yang Y, Donelan J, Jordan K, Tirrell S, Stringer B, Xia C, Hather G, Galvin K, Manfredi M, Rhodes N, Amidon B.
PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0144825Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells.
Engür S, Dikmen M, Öztürk Y.
Immunopharmacol Immunotoxicol · comparative study; research support, non-u.s. gov't; journal article · DOI 10.3109/08923973.2015.1122616Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species.
Garcia JS, Huang M, Medeiros BC, Mitchell BS.
Clin Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/1078-0432.ccr-15-1440Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
Gupta N, Goh YT, Min CK, Lee JH, Kim K, Wong RS, Chim CS, Hanley MJ, Yang H, Venkatakrishnan K, Hui AM, Esseltine DL, Chng WJ.
J Hematol Oncol · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1186/s13045-015-0198-1Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model.
Reese SR, Wilson NA, Huang G, Redfield RR, Zhong W, Djamali A.
Transplantation · research support, non-u.s. gov't; journal article · DOI 10.1097/tp.0000000000000736Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib.
Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A.
Blood Cancer J · clinical trial, phase ii; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/bcj.2015.60Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.
Gupta N, Huh Y, Hutmacher MM, Ottinger S, Hui AM, Venkatakrishnan K.
Cancer Chemother Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1007/s00280-015-2815-7Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
Gupta N, Zhao Y, Hui AM, Esseltine DL, Venkatakrishnan K.
Br J Clin Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/bcp.12542Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
Smith DC, Kalebic T, Infante JR, Siu LL, Sullivan D, Vlahovic G, Kauh JS, Gao F, Berger AJ, Tirrell S, Gupta N, Di Bacco A, Berg D, Liu G, Lin J, Hui AM, Thompson JA.
Invest New Drugs · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s10637-015-0230-xThe investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
Richardson PG, Moreau P, Laubach JP, Gupta N, Hui AM, Anderson KC, San Miguel JF, Kumar S.
Future Oncol · review; journal article · DOI 10.2217/fon.15.9Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG.
Lancet Oncol · clinical trial, phase ii; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1016/s1470-2045(14)71125-8Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.
Assouline SE, Chang J, Cheson BD, Rifkin R, Hamburg S, Reyes R, Hui AM, Yu J, Gupta N, Di Bacco A, Shou Y, Martin P.
Blood Cancer J · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1038/bcj.2014.71An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma.
Offidani M, Corvatta L, Caraffa P, Gentili S, Maracci L, Leoni P.
Onco Targets Ther · review-article; review; journal article · DOI 10.2147/ott.s49187Oral therapy for multiple myeloma: ixazomib arriving soon.
Moreau P.
Blood · article-commentary; comment; journal article · DOI 10.1182/blood-2014-06-581611Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, Lonial S.
Blood · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1182/blood-2014-01-548826Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
Kumar SK, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D, Hui AM, Gupta N, Di Bacco A, Yu J, Shou Y, Niesvizky R.
Blood · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1182/blood-2014-01-548941The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs.
Paulus A, Masood A, Miller KC, Khan AN, Akhtar D, Advani P, Foran J, Rivera C, Roy V, Colon-Otero G, Chitta K, Chanan-Khan A.
Br J Haematol · research support, non-u.s. gov't; journal article · DOI 10.1111/bjh.12731(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.
Duncan K, Rosean TR, Tompkins VS, Olivier A, Sompallae R, Zhan F, Tricot G, Acevedo MR, Ponto LL, Walsh SA, Tygrett LT, Berger AJ, Waldschmidt T, Morse HC, Sunderland JJ, Janz S.
Blood Cancer J · research-article; journal article · DOI 10.1038/bcj.2013.61New orally active proteasome inhibitors in multiple myeloma.
Allegra A, Alonci A, Gerace D, Russo S, Innao V, Calabrò L, Musolino C.
Leuk Res · review; journal article · DOI 10.1016/j.leukres.2013.10.018Boronic acid-containing proteasome inhibitors: alert to potential pharmaceutical bioactivation.
Li AC, Yu E, Ring SC, Chovan JP.
Chem Res Toxicol · research support, non-u.s. gov't; journal article · DOI 10.1021/tx400032n